Answers are grounded in this paper and cite their sources.
It has been a longstanding ambition of interventional cardiologists to overcome the limitations of a considerable rate of adverse events of metallic drug-eluting stents (DES) which remain inside the treated vessel permanently. Bioresorbable scaffolds (BRS) provide a potential solution, allow positive remodeling, reduce inflammation, long-term stent thrombosis (ST), and in-stent restenosis (ISR). The Fantom BRS is a novel second-generation radiopaque polymer scaffold based on Tyrocore that disappears completely in a timeframe of 4 years. Tyrocore offers several advantages over Poly L-lactic acid (PLLA) based BRS including inflammation, strength and visibility. We retrospectively collected and analyzed the patient-related baseline, peri- and postprocedural data of patients in whom at least one Fantom BRS was implanted at the Kantonsspital Baselland from 2017 to 2022 by a single operator. Target lesion revascularization (TLR), ST and overall death were assessed. There were 59 patients included in this study who received a total of 84 BRS, accounting for a mean of 1.42 BRS per patient. The mean age was 60.5±11.0 years, the mean lesion length 23.6±7.2 mm and the mean reference diameter 3.2±0.3 mm. Mean calcification was mild and in 18 (30.5%) of patients an optical coherence tomography (OCT) was performed. The mean time of follow up was 30±20 months. During follow up, there was 1 case (1.7%) of target lesion revascularization, there were no stent thromboses and no deaths. The Fantom BRS is a safe and feasible alternative to conventional DES in eligible patients. Further studies with a larger patient collective and a prospective design are needed to evaluate a possible benefit on relevant endpoints compared to state-of-the-art DES.
No takes yet. Share an insight, caveat, or question.
Czopak et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: